DDL2022: Inhalation Sciences had several landmark presentations at well-attended event
At this year’s DDL in Edinburgh, Scotland (7-9 December) Inhalation Sciences AB (ISAB) presented, for the first time, data from its clinical study of PreciseInhale, showing how the system out-performed commercial inhalers in targeting aerosols to specified regions of the lung. A second poster on ISAB’s in vitro simulation module DissolvIt was also presented. This was the first onsite DDL event since the end of European Covid-19 restrictions.DDL conferences (Drug Delivery to the Lungs) are some of the most well-attended events in the global inhalation industry’s calendar. As the first DDL